Company Description
Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States.
It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey. As of August 26, 2024, Agile Therapeutics, Inc. operates as a subsidiary of Exeltis USA, Inc.
| Country | United States |
| Founded | 1997 |
| IPO Date | May 23, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Alfred Altomari |
Contact Details
Address: 500 College Road East, Suite 310 Princeton, New Jersey 08540 | |
| Phone | 609 683 1880 |
| Website | agiletherapeutics.com |
Stock Details
| Ticker Symbol | AGRX |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001261249 |
| CUSIP Number | 00847L100 |
| ISIN Number | US00847L3087 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alfred F. Altomari | Chairman, President and Chief Executive Officer |
| Scott M. Coiante | Chief Financial Officer, Senior Vice President and Treasurer |
| Geoffrey P. Gilmore | Senior Vice President, Chief Administrative Officer and Corporate Secretary |
| Dr. Paul Korner M.B.A., M.D. | Senior Vice President and Chief Medical Officer |
| Robert G. Conway M.E. | Senior Vice President and Chief Corporate Planning and Supply Chain Officer |
| Amy Welsh | Senior Vice President and Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 28, 2024 | RW | Filing |
| Aug 27, 2024 | EFFECT | Notice of Effectiveness |
| Aug 27, 2024 | EFFECT | Notice of Effectiveness |
| Aug 27, 2024 | EFFECT | Notice of Effectiveness |
| Aug 26, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 26, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 26, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 26, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 26, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 26, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |